Recruiting

Observational Study

Sponsor:

Uromedica

Code:

NCT03767595

Conditions

Stress Urinary Incontinence

Eligibility Criteria

Sex: Male

Age: 50+

Healthy Volunteers: Accepted

Interventions

ProACT Adjustable Continence Therapy for Men

Study Details

Brief summary:

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Conditions

Stress Urinary Incontinence

Study ID

NCT03767595

Start date

Feb 19, 2019

Status verified date

Oct, 2026

Completion date

Dec 31, 2031

Anticipated

Primary completion date

Dec 31, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 50+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Subject is a male of at least 50 years of age.
2. Subject demonstrates stress urinary incontinence.
3. Subject has undergone a radical prostatectomy, transurethral resection of the prostate, or other prostate surgery.
4. Subject is willing and able to undergo surgical implantation of ProACT devices.
5. Subject is willing and able to comply with study-required

follow-up activities, including annual telephonic follow -up interviews, for a period of 5 years from their date of initial implantation. This includes compliance even after possible explant of ProACT devices and/or possible implantation of subsequent therapies.
6. Subject is willing and able to sign the approved informed consent.
7. Subject has two positive 24-hour pad weight tests (greater than or equal to 8 gram pad weight increase demonstrated in two 24-hour pad weight tests).
8. Subject has a negative urine culture.
9. Subject has no known urogenital malignancy, other than previously treated prostate cancer.
10. Subject meets ONE of the following criteria:

1. Baseline Prostate-Specific Antigen (PSA) of less than or equal to 2.5ng/mL;
2. Baseline PSA > 2.5ng/mL and less than or equal to 10 ng/mL AND free PSA greater than or equal to 25% of total PSA;
11. Physician determines subject to be a suitable surgical candidate.

Exclusion Criteria:

1. Subject has an existing urethral stricture, a history of any urethral strictures, or has ever had a urethrotomy.
2. Subject has undergone prostate surgery or any anti-incontinence surgery within the last 12 months.
3. Subject has an artificial urinary sphincter or any components of a previously implanted artificial urinary sphincter in vivo.
4. Subject has undergone radiation therapy in the prostatic area within the last 12 months.
5. Subject has untreated or unsuccessfully treated detrusor instability or over-activity.
6. Subject has an atonic bladder.
7. Subject had, presently has, or is suspected of having bladder cancer.
8. Subject has untreated or unsuccessfully treated bladder stones.
9. Subject has detrusor sphincter dyssynergia.
10. Subject has known hemophilia or a bleeding disorder.
11. Subject has a known severe contrast solution allergy (e.g., anaphylaxis, cardiac, or respiratory arrest).
12. Subject has insulin-dependent diabetes that is uncontrolled or not controllable, as indicated by an A1c test result of = 6.5%.

Study Design

Enrollment

145 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: ProACT Adjustable Continence Therapy for Men

Patients implanted with ProACT Adjustable Continence Therapy for Men

Interventions

ProACT Adjustable Continence Therapy for Men

The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.

Primary outcome measure

  • Urethral Strictures [ Time Frame: 5 years ]
  • Device Erosions [ Time Frame: 5 years ]
  • Incontinence Quality of Life Questionnaire (I-QoL) [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Locations

University of Southern California

Recruiting

Los Angeles, California, United States, 90033

Contacts

Principal Investigator:

Jeffrey Loh-Doyle, MD

Sutter Health

Recruiting

Santa Barbara, California, United States, 93110

Contacts

Principal Investigator:

Scott Tobis, MD

University of Colorado

Recruiting

Denver, Colorado, United States, 80045

Contacts

Principal Investigator:

Brian Flynn, MD

University of Florida

Recruiting

Gainesville, Florida, United States, 32610

Contacts

Principal Investigator:

Lawrence Yeung, MD

Urological Research Network Corp

Recruiting

Hialeah, Florida, United States, 33016

Contacts

Principal Investigator:

Edward Gheiler, MD

Emory University

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Nahir Imtiaz

sbimtia@emory.edu

Principal Investigator:

Lindsey Hartsell, MD

University of Kansas Medical Center

Recruiting

Kansas City, Kansas, United States, 66103

Contacts

University of Michigan

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Principal Investigator:

Bahaa Malaeb, MD

CentraCare- St. Cloud

Recruiting

Saint Cloud, Minnesota, United States, 56303

Contacts

CHI Health Research

Recruiting

Omaha, Nebraska, United States, 68124

Contacts

Principal Investigator:

Michael Feloney, MD

Lehigh Valley Health Network

Recruiting

Allentown, Pennsylvania, United States, 18103

Contacts

Megan McGonagle, MSN, RN, PCCN

Megan.mcgonagle@jefferson.edu

Principal Investigator:

Matthew Loecher, MD

Allegheny Health Network

Recruiting

Pittsburgh, Pennsylvania, United States, 15212

Contacts

Principal Investigator:

Kiran Sury, MD

Urology Partners of North Texas Research Institute

Recruiting

Arlington, Texas, United States, 76017

Contacts

Principal Investigator:

Keith Xavier, MD

DHR Health Institute for Research and Development

Recruiting

McAllen, Texas, United States, 78504

Contacts

Principal Investigator:

Henry Ruiz, MD

More Information

Sponsor

Uromedica

Last update posted

Oct 6, 2026

Last verified

Oct, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by Uromedica on 2026-10-06. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.